European Biopharmaceutical Review |
 |
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
| An introduction to the themes of EBR Summer from Editor Helen Tayton-Martin |
|
|
|
| In Markets Reloaded, Christian Tidona of Tidona Consulting GmbH and Peter Liepolt of trio-financial relations AG review current trends in the capital markets |
|
|
| In The Business Alchemist, Nigel Wild at Nigel Wild Associates looks at the formative years of a biotech start-up and the conditions conducive to longevity |
|
|
| From increased access to capital to losses in management time, Keith White at Critchleys considers the potential perils and pay-offs of flotation, in The Buoyancy of Floating |
|
|
|
| In The Spin-Out Life Cycle, Mark Lomas at Ashfords and Michael Roberts of Greaves Brewster LLP explore the legal and IP minefields of founding and developing a biotech enterprise |
|
|
| Tim Jinks of BTG discusses the merits of Tapping New Pipelines, and forming partnerships and licensing agreements early on in the development process |
|
|
| With a particular focus on the Bolar exemptions, Aura Soininen and Ben Rapinoja at Borenius & Kemppinen Ltd assess the latest moves in European implementation of pharmaceutical legislation, in Enacting Exemption |
|
|
| In the context of an industry where collaboration is evermore important, Dr Duncan Curley at McDermott Will & Emery UK LLP takes up A Matter of Possession - the critical issue of intellectual property |
|
|
|
| With significant international variations in legal and ethical attitudes towards stem cell research, the prospect of therapies making it to market is uncertain. In Roots and Shoots - The Future of Stem Cells, Himanshu Parmar at Frost & Sullivan considers both the potential and the problems of this field |
|
|
| Dr James Miskin, Professor Susan Kingsman and Dr Kyriacos Mitrophanous at Oxford Biomedica provide an overview of developments in the use of integrating vectors to introduce genes to target cells, in Ingenious Therapy |
|
|
| Dr Ansgar Santel of SR Pharma plc/Atugen AG investigates a valuable technology, both in vivo and in vitro, in RNAi: The Secrets of Silence Uncovered |
|
|
| With greater affinity and biostability, third generation compounds based on LNA chemistry are a promising therapeutic avenue. In RNAi Antagonism: The New Meaning of Antisense, Keith McCullagh of Santaris Pharma looks at this development in switching-off disease-causing genes |
|
|
|
|
| Gunilla Hššg at Recip AB illustrates the successful implementation of a new laboratory information management system, in LIMS Lifts Confidence |
|
|
| In Reaping the Benefits of New Microarray Technology, Jordan Stockton at Agilent Technologies delves into the expanding uses of this technique |
|
|
| Steven Reynolds and Damir Blazina at Oxford Instruments Molecular Biotools explain how nuclear magnetic resonance spectroscopy is providing solutions to the need to isolate higher quality leads in a target-rich environment, in One Small Acronym for Man, One Giant Leap for NMR |
|
|
| John Favier at DEM Solutions ventures into A Virtual Reality in his discussion of computer aided design and its cost- and time-saving possibilities |
|
|
|
| The intricacies of the 2004 act on human tissue use and storage continue to unfold in a second article by Neil Sullivan at Cord8 Ltd - The Human Factor: Part II |
|
|
| It makes good sense to investigate possible harmful effects on the heart at the earliest stages of drug development. Dr Simon Bryant and Dr Derek Terrar at Oxford Cardiac Pharmacology Ltd (OCP) address Matters of the Heart: Assessing Cardiac Side Effects |
|
|
| With a host of patents on the verge of expiration, biogenerics are receiving increasing attention; Dr Conrad Savoy of Biopartners weighs the issues In a Biosimilar Vein |
|
|
| In our second article on biogenerics - Tackling the Brand Nation - Dr Faiz Kermani at Chiltern details the hurdles to be overcome in order to maximise the potential of this new class of drug |
|
|
|
| Gerald Adams of Lyosolutions elucidates the complexities of freeze-drying and investigates its increasing range of applications, in A New Ice Age |
|
|
| In Making Vaccines Safer: Progress Toward Animal-Free Production, David Mead, Dermot Pearson and Maree Devine at Delta Biotechnology Limited review the problems attending animal-derived protein products and the solutions offered by alternative sources |
|
|
|
|
| With a focus on financial incentives and policies to promote skills development and research, such as the Research Tax Credit, Geraldine Filippi at Invest in France uncovers Europe's third largest market, in Boosting Biotech the French Way |
|
|
|
|
| In Goteborg: In the Realm of Research, Olivia Lindau-Jonsson and Anders Linnard at Business Region Goteborg review the biomedical history of the region and consider how this supports continuing innovation in fields such as cardiovascular therapy, biomaterials and metabolic diseases |
|
|
| With over 200 biotech companies and 130 products in late preclinical or clinical trials, Sweden has the fourth largest biotech industry in Europe. Ylva Williams at Invest in Sweden Agency illuminates the national biotech scene in terms of finance, centres of academic excellence, traditions in drug development and more, in Northern Lights |
|
|
|
|
|
.jpg)
